Wall Street analyst estimates for argenx SE (ARGX): consensus price target, buy/hold/sell recommendations and forecasts for revenue and EPS for the upcoming fiscal years.
argenx SE, a biotechnology company established in Amsterdam, the Netherlands, in 2008, is dedicated to developing innovative therapies primarily for autoimmune diseases. The company's operations span across key global markets, including the United States, Japan, Europe, the Middle East, Africa, and China. Its leading investigational therapy is efgartigimod, which is being developed to address a broad range of conditions.
Consensus price target
$1,133.33 (+30 % vs price $869.33)
between $861.00 and $1,400.00 · 22 targets published in the last quarter
Closing price, Oct 28
A twelve-month target is not a fair value: compare it with the range in the Valuation tab.
Revenue and EPS estimates
| Fiscal year | Revenue (average) | Revenue (low – high) | EPS (average) | Analysts |
|---|---|---|---|---|
| 2026E | $6.3B | $6.2B – $6.5B | $28.78 | 9 |
| 2027E | $7.9B | $7.5B – $8.5B | $37.65 | 9 |
Figures in USD · consensus as of October 29, 2026
Analyst Consensus
| Strong Buy | 1 |
| Buy | 31 |
| Hold | 4 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 36 |
| Avg rating (−2 sell to +2 buy) | 0.92 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2027-02-25 | $7.79 | ||
| 2026-07-30 | $7.80 | $7.44 | +4.8% |
| 2026-05-07 | $5.90 | $5.16 | +14.3% |
| 2025-10-30 | $5.18 | $4.37 | +18.5% |
| 2025-05-08 | $2.58 | $2.32 | +11.2% |
| 2024-10-31 | $1.39 | $0.10 | +1290.0% |
| 2024-05-09 | $-1.04 | $-0.71 | -46.5% |
| 2023-10-31 | $-1.25 | $-1.54 | +18.8% |
Valuation Ratios
| P/E Ratio | 41.71 |
| Price / Book | 6.61 |
| EV / EBITDA | 37.73 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $15.5M | $43.7M | $24.6M | $78.5M | $41.2M | $1.08B | $410.7M | $1.23B | $2.19B | $4.15B |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 | $580.5M | $29.4M | $117.8M | $227.3M | $450.7M |
| Gross Profit | $15.5M | $43.7M | $24.6M | $78.5M | $41.2M | $497.3M | $381.3M | $1.11B | $1.96B | $3.70B |
| Research & Development | $33.2M | $62.1M | $95.6M | $220.8M | $370.5M | $580.5M | $663.4M | $859.5M | $983.4M | $1.36B |
| Selling, General & Admin | $7.4M | $14.9M | $26.3M | $72.1M | $170.6M | $305.5M | $469.9M | $709.5M | $1.06B | $1.36B |
| Operating Expenses | $38.0M | $71.2M | $118.2M | $277.4M | $518.9M | $846.0M | $1.10B | $1.53B | $1.98B | $2.65B |
| Operating Income | -$22.5M | -$27.5M | -$93.6M | -$198.9M | -$477.6M | -$348.7M | -$720.3M | -$425.0M | -$21.7M | $1.05B |
| EBITDA | -$22.2M | -$32.4M | -$93.1M | -$173.4M | -$601.0M | -$392.8M | -$622.8M | -$192.3M | $105.2M | $1.31B |
| Interest Expense | 0 | 0 | 0 | $139,000 | $403,657 | $1.1M | $2.2M | $904,000 | $2.2M | $4.1M |
| Pre-tax Income | -$22.5M | -$33.0M | -$75.3M | -$175.9M | -$605.4M | -$399.7M | -$729.3M | -$304.5M | $85.2M | $1.28B |
| Income Tax | 0 | $716,222 | $908,258 | $5.3M | $3.1M | $8.5M | -$19.7M | -$9.4M | -$747.9M | -$13.4M |
| Net Income | -$22.5M | -$33.7M | -$76.2M | -$181.2M | -$608.5M | -$408.3M | -$709.6M | -$295.1M | $833.0M | $1.29B |
| EPS | $-1.19 | $-1.37 | $-2.12 | $-4.69 | $-13.40 | $-7.99 | $-13.05 | $-5.16 | $13.92 | $21.14 |
| EPS (Diluted) | $-1.20 | $-1.37 | $-2.12 | $-4.69 | $-13.40 | $-7.99 | $-13.05 | $-5.16 | $12.78 | $19.63 |
| Shares Outstanding (Diluted) | 18.8 M | 24.6 M | 36.0 M | 38.6 M | 45.4 M | 51.1 M | 54.4 M | 57.2 M | 65.2 M | 66.0 M |
Price
| Price | $869.33 (closing price, October 28, 2026) |
| Market Cap | $54.7B |
| Exchange | NASDAQ |
| Country | NL |
Related companies: AMGN · BIIB · INCY · TGTX
Explore sector: Healthcare · Biotechnology
More sections of ARGX: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks